CKD Bio Corp. (KRX:063160)

CKD Bio Revenue

CKD Bio had revenue of 42.34B KRW in the quarter ending September 30, 2023, with 12.64% growth. This brings the company's total for the last twelve months to 159.93B, up 3.59% year-over-year. In the year 2022, CKD Bio had annual revenue of 156.04B with 9.70% growth. That makes CKD Bio the 21,325th largest company in the world by revenue and 1,159th in South Korea.

• Revenue (ttm): 159.93B
• Revenue Growth: +3.59%
• P/S Ratio: 0.41
• Revenue / Employee: 308.16M
• Employees: 519
• Market Cap: 65.78B

Revenue Chart

Chart

Chart

Revenue by Segment

Chart

• Raw Drug Product Division 125.09B 80.2%
• Probiotics Division 24.98B 16.0%
• Botulinum Toxin Division 5.97B 3.8%

Fiscal year ended Dec 31, 2022

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2022	156.04B	13.80B	9.70%
Dec 31, 2021	142.24B	17.64B	14.16%
Dec 31, 2020	124.60B	-12.58B	-9.17%
Dec 31, 2019	137.18B	12.67B	10.18%
Dec 31, 2018	124.51B	10.75B	9.45%

Data Source: S&P Global Market Intelligence Last updated: Nov 14, 2023

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 1, 2026

Data Sources Report a data error